Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing

Lu-Lu Yang; Xu-Chao Zhang; Shao-Kun Chuai; Zhi-Hong Chen; Zhi Xie; Wei-Bang Guo; Shi-Liang Chen; Yuan-Yuan Lei; Long-Hua Guo; LanYing Gou; Hui-Wen Sun; Qi Zhang; Jin-Ji Yang; Hai-Yan Tu; Jian Su; Yi-Long Wu

doi:10.1016/j.jgg.2015.09.007

Volume 42 Issue 10

Oct. 2015

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2015 > 42(10): 579-587

PDF( 991 KB)

Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing

doi: 10.1016/j.jgg.2015.09.007

a
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China
b
The First Clinic College of South China University of Technology, Guangzhou 510080, China
c
Burning Rock Biotech, Guangzhou 510300, China
d
First Department of Chemotherapy, Meizhou People Hospital, Meizhou, Guangdong 514000, China

More Information

Corresponding author: E-mail address: syylwu@live.cn (Yi-Long Wu)
Received Date: 2015-06-13
Accepted Date: 2015-09-06
Rev Recd Date: 2015-08-27

Available Online: 2015-09-30

Publish Date: 2015-10-20

Abstract

Abstract

Few effective therapies have been developed for the treatment of lung squamous cell carcinoma (SQCC), in part due to a lack of understanding regarding the mechanisms underlying the initiation and development of this disease. Whole transcriptome sequencing not only provides insight into the expression of all transcribed genes, but offers an efficient approach for identifying genetic variations, including gene fusions, mutations and alternative splicing. In this study, we performed whole transcriptome sequencing of 10 patients with stage IIIA lung SQCC, and discovered a large number of single nucleotide variants (SNVs; mean of 12.2 SNVs/Mb), with C>T/G>A and A>G/T>C transitions being the most frequently observed. Additionally, a total of 132 gene fusions were identified based upon TopHat alignments, 70.5% (93/132) of which occurred as a result of intra-chromosomal rearrangements. Based on the number of supporting reads for each fusion, we further validated 20 of the 26 top gene fusions by RT-PCR and Sanger sequencing. Taken together, these data provide an in-depth view of transcriptional alterations in lung SQCC patients, and may be useful for identification of new therapeutic targets.
- Lung squamous cell carcinoma,
- Transcriptome sequencing,
- Gene fusion

FullText(HTML)

References(19)

References

[1]	An, S.J., Chen, Z.H., Su, J. et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status PloS One, 7 (2012),p. e40109
[2]	Ding, L., Getz, G., Wheeler, D.A. et al. Somatic mutations affect key pathways in lung adenocarcinoma Nature, 455 (2008),pp. 1069-1075
[3]	Forbes, S.A., Bindal, N., Bamford, S. et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer Nucleic Acids Res., 39 (2011),pp. D945-950
[4]	Govindan, R., Ding, L., Griffith, M. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers Cell, 150 (2012),pp. 1121-1134
[5]	Ju, Y.S., Lee, W.C., Shin, J.Y. et al. Genome Res., 22 (2012),pp. 436-445
[6]	Kim, D., Salzberg, S.L. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts Genome Biol., 12 (2011),p. R72
[7]	Kohno, T., Ichikawa, H., Totoki, Y. et al. Nat. Med., 18 (2012),pp. 375-377
[8]	Leary, R.J., Kinde, I., Diehl, F. et al. Development of personalized tumor biomarkers using massively parallel sequencing Sci. Transl. Med., 2 (2010)
[9]	Lee, S.Y., Kim, M.J., Jin, G. et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers J. Thorac. Oncol., 5 (2010),pp. 1734-1740
[10]	Lee, W., Jiang, Z., Liu, J. et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient Nature, 465 (2010),pp. 473-477
[11]	Mok, T.S., Wu, Y.L., Thongprasert, S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med., 361 (2009),pp. 947-957
[12]	Pikor, L.A., Ramnarine, V.R., Lam, S. et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications Lung Cancer, 82 (2013),pp. 179-189
[13]	Pleasance, E.D., Stephens, P.J., O'Meara, S. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure Nature, 463 (2010),pp. 184-190
[14]	Shaw, A.T., Ou, S.H., Bang, Y.J. et al. N. Engl. J. Med., 371 (2014),pp. 1963-1971
[15]	Solomon, B.J., Mok, T., Kim, D.W. et al. N. Engl. J. Med., 371 (2014),pp. 2167-2177
[16]	The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature, 489 (2012),pp. 519-525
[17]	Trapnell, C., Pachter, L., Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq Bioinformatics, 25 (2009),pp. 1105-1111
[18]	Trapnell, C., Williams, B.A., Pertea, G. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation Nat. Biotechnol., 28 (2010),pp. 511-515
[19]	Zhang, J., Chiodini, R., Badr, A. et al. The impact of next-generation sequencing on genomics J. Genet. Genomics, 38 (2011),pp. 95-109